Novo Nordisk just killed its deal with Hims & Hers. But Hims might come out stronger after this development. Read why the ...

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

ヒムズ＆ハーズ45.95（-18.27 -28.45%） 肥満薬の調剤版を販売する遠隔医療プラットフォームのヒムズ＆ハーズ・ヘルスが大幅安。デンマークのノボ・ノルディスクが同社との提携を終了したと発表したことが嫌気されている。

（ＮＹ時間０８：１８）（日本時間２１：１８）時間外ヒムズ＆ハーズ＜ＨＩＭＳ＞　５０．９６（－１３．２６　－２０．６５％）　肥満薬の調剤版を販売する遠隔医療プラットフォームのヒムズ＆ハーズ・ヘルス＜ＨＩＭＳ＞が時間外で大幅安・・・。

Novo Nordisk alleged that Hims & Hers is putting patient safety at risk by selling compounded versions of Wegovy. Novo's ...

I am receiving several questions from investors inquiring about this growth stock following its significant price decline.

Hims & Hers (NYSE: HIMS) stock investors desperately need some positive news following the stock price crash in late June. Where to invest $1,000 right now? Our analyst team just revealed what they ...

Hims & Hers extended its rally for the second day on Friday, adding 6.76 percent to close at $49.41 apiece after its chief ...

Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for ...

The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's largest pharmaceutical companies.

The fortune of the San Francisco-based telehealth company’s cofounder and chief executive, Andrew Dudum, crumbled by more ...

Hims & Hers Health Inc. (NYSE: HIMS) shares are trading higher Thursday. The stock appears to be bouncing back a bit after ...